In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the audio recording of the Company''s Earnings Call held today (i.e., August 16, 2022) regarding discussion on operational and financial performance for the First Quarter of FY 2022-2023 (Q1) is available on the Company''s website. The recording can be accessed from the link given below: https://supriyalifescience.com/investor-relation/financial/earning-call-recordings/ You are requested to kindly take the same on record.
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that the Officials of Supriya Lifescience Limited ('Company') had interacted with institutional investors/analysts on June 13, 2022 via video conference. This is to further inform that the copy of the Investor Presentation which was referred during the meeting has been already uploaded on the website of the Company www.supriyalifescience.com and is also available on the Stock Exchanges for the public at large. No unpublished price sensitive information (UPSI) was discussed during the interactions. Request you to kindly take the same on record.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby enclose the transcript of the Earnings call held on Monday, May 23, 2022 at 3.30 P.M. IST to discuss operational and financial performance of the Company for the fourth quarter and year ended March 31, 2022. This is for your information and records.
In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the audio recording of the Company''s Earnings Call held today (i.e., May 23, 2022) regarding discussion on operational and financial performance for the Fourth Quarter and Financial Year ended March 31, 2022 (Q4 and FY 2021-22) is available on the Company''s website. The recording can be accessed from the link given below: https://supriyalifescience.com/investor-relation/financial/earning-call-recordings/ Kindly take the information on record.
Conference Call with Supriya Lifescience Manhttps://youtu.be/CvlNlXdt8Ksagement and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that the Officials of Supriya Lifescience Limited ('Company') had interacted with institutional investors/analysts on March 16, 2022 via video conference. This is to further inform that the copy of the Investor Presentation which was referred during the meeting has been already uploaded on the website of the Company www.supriyalifescience.com and is also available on the Stock Exchanges for the public at large. No unpublished price sensitive information (UPSI) was discussed during the interactions. Request you to kindly take the same on record.
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that the Officials of Supriya Lifescience Limited ('Company') had interacted with institutional investors/analysts on March 14, 2022 via video conference. This is to further inform that the copy of the Investor Presentation which was referred during the meeting has been already uploaded on the website of the Company www.supriyalifescience.com and is also available on the Stock Exchanges for the public at large. No unpublished price sensitive information (UPSI) was discussed during the interactions. Request you to kindly take the same on record.
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that the Officials of Supriya Lifescience Limited ('Company') had interacted with institutional investors/analysts on March 7, 2022 via video conference. This is to further inform that the copy of the Investor Presentation which was referred during the meeting has been already uploaded on the website of the Company www.supriyalifescience.com and is also available on the Stock Exchanges for the public at large. No unpublished price sensitive information (UPSI) was discussed during the interactions. Request you to kindly take the same on record.
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that the Officials of Supriya Lifescience Limited ('Company') had interacted with institutional investor/analyst on March 4, 2022 via video conference. This is to further inform that the copy of the Investor Presentation which was referred during the meeting has been already uploaded on the website of the Company www.supriyalifescience.com and is also available on the Stock Exchanges for the public at large. No unpublished price sensitive information (UPSI) was discussed during the interactions. Request you to kindly take the same on record.
